CRSP
Price
$48.52
Change
-$0.12 (-0.25%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
4.2B
41 days until earnings call
NVAX
Price
$6.61
Change
+$0.31 (+4.92%)
Updated
Jul 1, 04:59 PM (EDT)
Capitalization
1.02B
36 days until earnings call
Interact to see
Advertisement

CRSP vs NVAX

Header iconCRSP vs NVAX Comparison
Open Charts CRSP vs NVAXBanner chart's image
CRISPR Therapeutics AG
Price$48.52
Change-$0.12 (-0.25%)
Volume$54.13K
Capitalization4.2B
Novavax
Price$6.61
Change+$0.31 (+4.92%)
Volume$52.85K
Capitalization1.02B
CRSP vs NVAX Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. NVAX commentary
Jul 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and NVAX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 02, 2025
Stock price -- (CRSP: $48.64 vs. NVAX: $6.30)
Brand notoriety: CRSP: Not notable vs. NVAX: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 232% vs. NVAX: 38%
Market capitalization -- CRSP: $4.2B vs. NVAX: $1.02B
CRSP [@Biotechnology] is valued at $4.2B. NVAX’s [@Biotechnology] market capitalization is $1.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileNVAX’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • NVAX’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRSP and NVAX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 6 TA indicator(s) are bullish while NVAX’s TA Score has 2 bullish TA indicator(s).

  • CRSP’s TA Score: 6 bullish, 4 bearish.
  • NVAX’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than NVAX.

Price Growth

CRSP (@Biotechnology) experienced а +6.78% price change this week, while NVAX (@Biotechnology) price change was -0.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.51%. For the same industry, the average monthly price growth was +32.88%, and the average quarterly price growth was +3.93%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

NVAX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-0.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.2B) has a higher market cap than NVAX($1.02B). CRSP YTD gains are higher at: 23.577 vs. NVAX (-21.642). NVAX has higher annual earnings (EBITDA): 555M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. NVAX (731M). CRSP (219M) and NVAX (229M) have identical debt. NVAX has higher revenues than CRSP: NVAX (1.22B) vs CRSP (35M).
CRSPNVAXCRSP / NVAX
Capitalization4.2B1.02B412%
EBITDA-455.24M555M-82%
Gain YTD23.577-21.642-109%
P/E RatioN/A2.29-
Revenue35M1.22B3%
Total Cash1.86B731M254%
Total Debt219M229M96%
FUNDAMENTALS RATINGS
CRSP vs NVAX: Fundamental Ratings
CRSP
NVAX
OUTLOOK RATING
1..100
2557
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
4185
P/E GROWTH RATING
1..100
8050
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (67) in the Biotechnology industry is in the same range as NVAX (87). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NVAX (100). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as NVAX (100). This means that CRSP’s stock grew similarly to NVAX’s over the last 12 months.

CRSP's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for NVAX (85). This means that CRSP’s stock grew somewhat faster than NVAX’s over the last 12 months.

NVAX's P/E Growth Rating (50) in the Biotechnology industry is in the same range as CRSP (80). This means that NVAX’s stock grew similarly to CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPNVAX
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 7 days ago
79%
N/A
Declines
ODDS (%)
Bearish Trend 20 days ago
84%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UGE18.580.19
+1.02%
ProShares Ultra Consumer Staples
VSMV49.280.33
+0.68%
VictoryShares US Mult-Fctr Mnmm Vltl ETF
MORT10.560.07
+0.67%
VanEck Mortgage REIT Income ETF
PHK4.800.02
+0.42%
PIMCO High Income Fund
DIHP29.490.09
+0.31%
Dimensional International High Pbly ETF

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+4.15%
RXRX - CRSP
72%
Closely correlated
+0.70%
BEAM - CRSP
72%
Closely correlated
+1.25%
NTLA - CRSP
66%
Loosely correlated
-1.88%
PRME - CRSP
63%
Loosely correlated
+2.07%
ALLO - CRSP
63%
Loosely correlated
-4.24%
More

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with MRNA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
-1.10%
MRNA - NVAX
46%
Loosely correlated
+1.58%
ARCT - NVAX
43%
Loosely correlated
-2.40%
THRD - NVAX
42%
Loosely correlated
N/A
BNTX - NVAX
41%
Loosely correlated
-0.23%
CRSP - NVAX
39%
Loosely correlated
+4.15%
More